

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/004551

International filing date: 11 February 2005 (11.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/544,051
Filing date: 12 February 2004 (12.02.2004)

Date of receipt at the International Bureau: 11 March 2005 (11.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1290510

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 01, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/544,051

FILING DATE: February 12, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/04551



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

021204

23026 U.S. PTO

PTO/SB/16 (01-04)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

ER 228261576 US

22154 U.S. PTO
60/544051

021204

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
Thorsten	Schwenke	Chicago, IL			
Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Fluid composition used to simulate human synovial fluid					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number: 					
OR					
<input checked="" type="checkbox"/> Firm or Individual Name		Rush University Medical Center			
Address		Intellectual Property Office			
Address		1700 West Van Buren Street, Suite 470			
City		Chicago	State	IL	Zip
Country		USA	Telephone	312-563-2780	Fax
				60612	312-942-7224
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages <u>9</u> <input type="checkbox"/> CD(s), Number _____					
<input type="checkbox"/> Drawing(s) Number of Sheets _____ <input type="checkbox"/> Other (specify) _____					
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 80.00					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. FILING FEE Amount (\$)					
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees. 80.00					
<input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: _____ 80.00					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. 80.00					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME Matthew J. Raymond

TELEPHONE 312-563-2780

Date February 12, 2004

REGISTRATION NO. 45,035

(if appropriate)

Docket Number: R207

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

1 TITLE

2 Fluid composition used to simulate human synovial fluid

3
4 FIELD OF THE INVENTION

5 The present invention relates to a fluid composition used to simulate human synovial
6 fluid in the tribological analysis of artificial joints. More specifically, the invention
7 relates to a fluid composition used to simulate synovial fluid which generates wear
8 properties similar to human synovial fluid (involved in the tribological analysis of
9 artificial joints).

10
11 BACKGROUND OF THE INVENTION

12 In-vitro evaluation of implant performance is a standard practice in the design,
13 development, and manufacture of artificial hip and knee joints. In order to obtain
14 clinically relevant results from such tests, it is essential to simulate the in-vivo joint
15 conditions as closely as possible. Such joint conditions include the applied loads,
16 moments and displacements, the temperature, and the surrounding media present in the
17 joint. Fluid compositions to be used during in-vitro testing are commonly produced for
18 the purpose of simulating the human synovial fluid that naturally surrounds the joint in-
19 vivo. Various studies show the significant influence of chemical and physical parameters
20 of testing fluid in the wear outcome in joint material testing. The fluid composition
21 embodied by the present invention has been demonstrated to appropriately approximate
22 human synovial fluid while also generating clinically relevant results. These and other

1 objects and advantages of the present invention, as well as additional inventive features,
2 will be apparent from the description of the invention provided herein.

4 SUMMARY OF THE INVENTION

5 It is the object of the present invention to provide a fluid composition to be used in
6 simulating human synovial fluid during the tribological analysis of artificial joints.

7
8 It is another object of the present invention to provide a fluid composition possessing a
9 minimal influence on wear properties involved in the tribological analysis of artificial
10 joints.

11
12 The present invention relates to a fluid composition comprising a serum, a synthetic
13 amino acid, and water. In one aspect of the present invention, it is contemplated that the
14 serum of the fluid composition is bovine calf serum. It is further contemplated that the
15 synthetic amino acid of the fluid composition comprises Ethylene-Diamine-Tetra-
16 Acetate.

17
18 In another aspect the present invention relates to a fluid composition comprising a serum,
19 a fungicide and/or herbicide, and water. In one aspect of the present invention, it is
20 contemplated that the serum of the fluid composition is bovine calf serum. It is further
21 contemplated that the antibiotic solution of the fluid composition comprises Sodium
22 Azide. In this aspect, it is still further contemplated that the fluid composition might

1 additionally comprise a synthetic amino acid. It is contemplated that the synthetic amino
2 acid of the fluid composition is Ethylene-Diamine-Tetra-Acetate.

3
4 In another aspect the present invention relates to a fluid composition comprising a serum,
5 an antibiotic solution, and water. It is further contemplated that the antibiotic solution of
6 the fluid composition comprises Patricin. In this aspect, it is still further contemplated
7 that the fluid composition might additionally comprise a synthetic amino acid. It is
8 contemplated that the synthetic amino acid of the fluid composition is Ethylene-Diamine-
9 Tetra-Acetate.

11 DETAILED DESCRIPTION OF THE INVENTION

12 The present invention encompasses a fluid composition comprising a serum, an antibiotic
13 or fungicide/herbicide, a chelating agent, and water.

14
15 In a first preferred embodiment of the present invention, the serum of the fluid
16 composition is bovine calf serum. In this embodiment, the chelating agent of the fluid
17 composition comprises Ethylene-Diamine-Tetraacetic Acid (EDTA).

18
19 The second embodiment further encompasses the fluid composition consisting essentially
20 of about 25.0% to about 99.8% bovine calf serum, about 0.1% to about 3.0% EDTA, and
21 about 0.0% to about 67.0% deionized water, wherein the percentages of components are
22 weight to weight of the fluid composition.

1 In a second preferred embodiment of the present invention, the serum of the fluid
2 composition is bovine calf serum. In this embodiment, the fungicide and/or herbicide of
3 the fluid composition comprises Sodium Azide.

4
5 In a third preferred embodiment of the present invention, the serum of the fluid
6 composition is bovine calf serum. In this embodiment, the fungicide and/or herbicide
7 solution of the fluid composition comprises Sodium Azide. In this embodiment, the fluid
8 composition further comprises a synthetic amino acid. It is preferred that the chelating
9 agent is EDTA.

10
11 The third embodiment further encompasses the fluid composition consisting essentially
12 of about 25.0% to about 99.8% bovine calf serum, about 0.1% to about 5.0% Sodium
13 Azide, about 0.1% to about 3.0% EDTA, and about 0.0% to about 67.0% deionized
14 water, wherein the percentages of components are weight to weight of the fluid
15 composition.

16
17 In a fourth preferred embodiment of the present invention, the serum of the fluid
18 composition is bovine calf serum. In this embodiment, the antibiotic solution of the fluid
19 composition comprises Patricin.

20
21 In a fifth preferred embodiment of the present invention, the serum of the fluid
22 composition is bovine calf serum. In this embodiment, the antibiotic solution of the fluid

1 composition comprises Patricin A. In this embodiment, the fluid composition further
2 comprises a chelating agent. It is preferred that the chelating agent is EDTA.

3
4 The fifth embodiment further encompasses the fluid composition consisting essentially of
5 about 25.0% to about 98.0% bovine calf serum, about 0.1% to about 5.0% Patricin
6 solution, about 0.1% to about 3.0% EDTA, and about 0.0% to about 67.0% deionized
7 water, wherein the percentages of components are weight to weight of the fluid
8 composition.

9
10 It is envisioned that alternative chelating compounds such as Ethylene Glycol bis (2-
11 Aminoethyl Ether)-N,N,N',N'-Tetraacetic Acid (EGTA) or the sodium salts of EDTA can
12 be substituted freely for the chelating agent described above. Likewise, many antibiotic
13 and fungicide candidates exist which can be freely substituted for the described
14 embodiments. Finally, the newborn calf serum can be replaced by serum from any
15 available mammal, a number of manufacturers/retailers are available to purchase serum
16 from alternatives such as horses, dogs, etc. The newborn calf serum can be replaced with
17 fetal calf serum with a higher overall cost to the production.

18
19 While this invention has been described with an emphasis upon preferred embodiments,
20 it will be obvious to those of ordinary skill in the art that variations of the preferred
21 embodiments may be used and that it is intended that the invention may be practiced
22 otherwise than as specifically described herein. Accordingly, this invention includes all

1 modifications encompassed within the spirit and scope of the invention as defined by the
2 following claims.

3

4 **EXAMPLE 1:**

5 In this example, a solution is prepared for use in testing artificial hips. It is important to
6 be consistent in preparing the solution for each use as batch to batch variability may
7 impact test results.

8 The following materials are used in preparing the artificial synovial fluid. Each
9 component is available from multiple commercial suppliers.

- 10 - Newborn Calf Serum
- 11 - Patricin A
- 12 - EDTA
- 13 - Deionized water
- 14 - Mixing cylinder (2l)
- 15 - Heating bath capable of reaching 50°C
- 16 - Magnetic stirrer and stir bar
- 17 - Filter unit 0.22µm
- 18 - Filter unit 0.45µm

19 The artificial synovial fluid is prepared as follows:

20

- 21 1. Pre-heat the frozen calf serum in water bath to 37-39°C
- 22 2. Fill mixing cylinder with amount of calf serum needed for the target volume
23 according to the mixing ratios described herein
- 24 3. Add EDTA and Patricin A according to the mixing ratios described in Table 1.
- 25 4. Fill up the cylinder to the desired fluid amount
- 26 5. Mix the fluid (magnetic stirrer) for at least 15 min.
- 27 6. Filter the fluid first through the 0.22µm filter, then through the 0.45µm filter
- 28 7. Fill the fluid in squeeze bottle for use on simulator chambers

1 The fluid can be kept refrigerated for up to ten days.
2 300 ml of the fluid is then added to a Model HS2-12-1000, 12 Station Hip Simulator
3 (AMTI-Boston) to test wear on artificial hips according to experimental protocols. Fluid
4 is replaced in regular intervals of 1 to 3 days depending on the testing cycle.

5
6 **Table 1. Mixing Ratios for Example 1**
7

Final Vol [ml]	Serum [ml]	deionized water [ml]	EDTA [g]	Patricin [μg]
100	51.7	48.3	0.38	50
500	258.6	241.4	1.92	250
1000	517.2	482.8	3.85	500
2000	1034.5	965.5	7.70	1000

8
9 **CLAIMS**

10 **I Claim:**

- 11 1. A fluid composition used to simulate human synovial fluid in the
12 tribological analysis of artificial joints, wherein the fluid composition comprises a serum,
13 an antibiotic or fungicide and/or herbicide solution, and water.
- 14 2. The fluid composition of Claim 1, wherein the serum is bovine calf serum.
- 15 3. The fluid composition of Claim 1, wherein the fungicide and/or herbicide
16 solution comprises Sodium Azide.
- 17 4. The fluid composition of Claim 1, wherein the antibiotic solution
18 comprises Patricin A.
- 19 5. The fluid composition of Claim 1, further comprising a chelating agent.
- 20 6. The fluid composition of Claim 5 wherein the chelating agent is a
21 synthetic amino acid.

1 7. The fluid composition of Claim 5, wherein the chelating agent is chosen
2 from the group comprising Ethylene-Diamine-Tetraacetic Acid (EDTA), disodium
3 EDTA, tetra sodium EDTA, and Ethylene Glycol bis (2-Aminoethyl Ether)-N,N,N',N'-
4 Tetraacetic Acid (EGTA).

5 8. A fluid composition, consisting essentially of:
6 about 25.0% to about 99.9% bovine calf serum;
7 about 0.1% to about 3.0% Ethylene-Diamine-Tetra-Acetate; and
8 about 0.0% to about 72.0% deionized water,
9 wherein the percentages of components are weight to weight of the fluid
10 composition.

11 9. A fluid composition, consisting essentially of:
12 about 25.0% to about 99.8% bovine calf serum;
13 about 0.1% to about 5.0% Sodium Azide solution;
14 about 0.1% to about 3.0% Ethylene-Diamine-Tetra-Acetate; and
15 about 0.0% to about 67.0% deionized water,
16 wherein the percentages of components are weight to weight of the fluid
17 composition.

18 10. A fluid composition, consisting essentially of:
19 about 25.0% to about 99.8% bovine calf serum;
20 about 0.1% to about 5.0% Patricin A solution;
21 about 0.1% to about 3.0% Ethylene-Diamine-Tetra-Acetate; and
22 about 0.0% to about 67.0% deionized water,

- 1 wherein the percentages of components are weight to weight of the fluid
- 2 composition.